GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBY) » Definitions » Cyclically Adjusted PB Ratio

Medivir AB (Medivir AB) Cyclically Adjusted PB Ratio : (As of Jun. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Medivir AB Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Medivir AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Medivir AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Cyclically Adjusted PB Ratio Chart

Medivir AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.24 0.42 0.36 0.13

Medivir AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.27 0.27 0.13 0.13

Competitive Comparison of Medivir AB's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Medivir AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's Cyclically Adjusted PB Ratio falls into.



Medivir AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Medivir AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Medivir AB's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1/132.2054*132.2054
=1.000

Current CPI (Mar. 2024) = 132.2054.

Medivir AB Quarterly Data

Book Value per Share CPI Adj_Book
201406 7.008 100.432 9.225
201409 8.252 100.161 10.892
201412 8.314 100.225 10.967
201503 6.284 99.950 8.312
201506 6.806 99.995 8.998
201509 6.649 100.228 8.770
201512 6.361 100.276 8.386
201603 6.300 100.751 8.267
201606 6.180 101.019 8.088
201609 5.753 101.138 7.520
201612 6.992 102.022 9.061
201703 4.367 102.022 5.659
201706 3.958 102.752 5.093
201709 3.795 103.279 4.858
201712 3.016 103.793 3.842
201803 3.503 103.962 4.455
201806 2.763 104.875 3.483
201809 2.326 105.679 2.910
201812 1.677 105.912 2.093
201903 1.334 105.886 1.666
201906 1.253 106.742 1.552
201909 1.098 107.214 1.354
201912 0.963 107.766 1.181
202003 0.805 106.563 0.999
202006 0.784 107.498 0.964
202009 0.850 107.635 1.044
202012 0.835 108.296 1.019
202103 1.930 108.360 2.355
202106 1.863 108.928 2.261
202109 1.737 110.338 2.081
202112 1.523 112.486 1.790
202203 1.279 114.825 1.473
202206 1.105 118.384 1.234
202209 0.950 122.296 1.027
202212 0.915 126.365 0.957
202303 0.817 127.042 0.850
202306 0.676 129.407 0.691
202309 0.553 130.224 0.561
202312 1.046 131.912 1.048
202403 1.000 132.205 1.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medivir AB  (OTCPK:MVRBY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Medivir AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Medivir AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivir AB (Medivir AB) Business Description

Industry
Traded in Other Exchanges
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.